About the Psychiatry and Clinical Psychopharmacology

Psychiatry and Clinical Psychopharmacology is a peer reviewed, open access, online-only journal.

Psychiatry and Clinical Psychopharmacology is a quarterly journal that is published in English in March, June, September, and December. Psychiatry and Clinical Psychopharmacology is supported by the Turkish Association for Psychopharmacology.

Journal History
As of 2016, the journal has changed its title to Psychiatry and Clinical Psychopharmacology.

Current Title (2017 - …)
Psychiatry and Clinical Psychopharmacology
EISSN: 2475-0581

Previous Title (1990-2017)
Klinik Psikofarmakoloji Bülteni – Bulletin of Clinical Psychopharmacology
ISSN: 1302-9657
EISSN: 1302-9657

Abstracting and Indexing
Psychiatry and Clinical Psychopharmacology is covered in the following abstracting and indexing databases;

- Science Citation Index Expanded
- Scopus
- DOAJ
- Embase
- Gale
- CNKI
- HINARI
- Proquest: Proquest Psychology Journals
- Proquest Health&Medical Complete
- EBSCO
- Chemical Abstracts (CAS)
- TUBITAK ULAKBIM TR Index

All content published in the journal is permanently archived in Portico.

Aims, Scope, and Audience
Psychiatry and Clinical Psychopharmacology aims to publish studies of the highest scientific and clinical value, and encourages the submission of high-quality research that advances the understanding scientific fields such as psychiatry, child and adolescent psychiatry, neuroscience, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology covers a wide range of topics related to psychiatry and clinical psychopharmacology as well as forming a scientific forum by producing quality debate on various disciplines. The journal is interested in publishing original research that addresses important clinical questions and advances the understanding and treatment of these conditions. This may include studies on psychiatry, child and adolescent psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology publishes original research, reviews, case reports, letters to the editors, editorials, and short communications/brief reports within its scope. Conference proceedings may also be considered for publication.

The target audience of the journal includes specialists, residents, and scientists in psychiatry, psychology, neurology, neuroscience, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related disciplines.

Open Access Policy
Psychiatry and Clinical Psychopharmacology is an open access publication.

Starting on March 2021, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which allows third parties to read and share the material immediately upon publication for only non-commercial purposes by giving the appropriate credit to the original work. Adaptation and modification of the material is not permitted.

The content published before March 2021 was licensed under a traditional copyright, but the archive is still available for free access.

All published content is available online, free of charge at https://psychiatry-psychopharmacology.com/.

Authors retain unrestricted copyrights and publishing rights in Psychiatry and Clinical Psychopharmacology.
When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Copyright Policy
A Copyright Agreement and Acknowledgement of Authorship form should be submitted with all manuscripts. By signing this form, authors agree that the article, if accepted for publication by the Psychiatry and Clinical Psychopharmacology, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) which allows third parties to read and share the material immediately upon publication for only non-commercial purposes by giving the appropriate credit to the original work. Adaptation and modification of the material is not permitted.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Authors retain unrestricted copyrights and publishing rights in Psychiatry and Clinical Psychopharmacology.

Publication Fee Policy
Psychiatry and Clinical Psychopharmacology is funded by article processing charges (APC).

The article processing charge for the journal is 590 USD (updated in February 2021). Apart from the APC, there are no other fees or surcharges associated with the evaluation or publication process.

Authors are required to properly disclose any financial support they receive for the payment of the article processing charge.

Disclaimer
The statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the views of the editors, editorial board, and/or publisher. The editors, editorial board, and publisher are not responsible for the content of the manuscripts and do not necessarily endorse the views expressed in them. It is the responsibility of the authors to ensure that their work is accurate and well-researched, and the views expressed in their manuscripts are their own. The editors, editorial board, and publisher simply provide a platform for the authors to share their work with the scientific community.

You can find the current version of the Instructions to Authors at: https://psychiatry-psychopharmacology.com/en/instructions-to-authors-1020

Editor in Chief: Mesut Cetin, M.D., Professor of Psychiatry
Address: Bağdat Caddesi Birgen Plaza 226/7 Kadıköy 34728 İstanbul, Turkey
Mobile & Whatsapp: +90-532-272-3252
psikofarmakoloji@gmail.com

Publisher: AVES
Address: Büyükdere Cad. 199/6, 34394, Şişli, İstanbul, Türkiye
Phone: +90 212 217 17 00
E-mail address: info@avesyayincilik.com
www.avesyayincilik.com
CONTENTS

ORIGINAL ARTICLES

70 The Development of Psychosis in Patients with Substance Use Disorder and Its Association with Cavum Septum Pellucidum and Adhesio Interthalamica
Ceylan Ergül, Cumali Aydın, Bahruz Shukurov, Celal Şalçini, Necati Alp Tabak, Nesrin Dilbaz

76 The Association Between Clozapine Plasma Concentration, CYP2D6 (*10, *2) Polymorphisms and Risk of Adverse Reactions
Kankan Qu, Qin Zhou, Hashao Zhu, Zhenhe Zhou, Yuan Shen, Lin Tian, Xujing Su

84 Evaluation of Serum Complement Levels and Factors Affecting Treatment Resistance in Patients with Schizophrenia
Mustafa Goker, Hasan Mervan Aytac, Oya Guclu

94 Mechanisms in Emotional Information Processing in Individuals with Major Depressive Disorder: An Event-Related Potential Study of an Information Processing Model
Daniel Kwasiz Ahorsu, Ken Ho Ming Chung, Ho Hon Wong, Michael Gar Chung Yiu, Yat Fung Mok, Ka Shun Lei, Hector Wing Hong Tsang

108 The Relationship Between Depression, Anxiety and Stress Levels on Suicidal Behavior in Patients with Schizophrenia
Şafak Taktak, Hısal Seki Öz

117 Life Chart of Substance Use Career: A Clinical Profile Study from Turkey
Cavid Guliyev, Melike Simsek, Sevinc Bezek-Dino, Kultegin Ogel

126 The Relationship Between Suicidal Behavior, Neurocognitive Functions, and Insight in Patients with Schizophrenia
Sumeyye Yasemin Calic, Yagmur Sever Fidan, Engin Emrem Bestepe, Fıraz Izcı

134 Turkish Adaptation, Validity, and Reliability Study of Shitsu-Taikan-Sho (Alexisomia) Scale
Muhammed Hakan Aksu, Nur Nihal Baltacs, Irem Ekmekçi Ertek, Behyet Coşar

CASE REPORT

143 Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report
Mahmut Selçuk

REVIEW

147 Resveratrol in Neurodegeneration, in Neurodegenerative Diseases, and in the Redox Biology of the Mitochondria
Betül Danışman, Sevim Ercan Kelek, Mutay Aslan